{"id":732825,"date":"2023-02-21T06:33:17","date_gmt":"2023-02-21T11:33:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/"},"modified":"2023-02-21T06:33:17","modified_gmt":"2023-02-21T11:33:17","slug":"in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/","title":{"rendered":"In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-top:6pt;margin-bottom:8pt\">FTD is a rare and rapidly progressing neurodegenerative disease caused by multiple hereditary factors, including mutations in the progranulin (<em>GRN<\/em>) gene<\/li>\n<li style=\"margin-top:6pt;margin-bottom:8pt\">The observational EFRONT study is increasing the number of sites to expand access to geographic specific clinicians actively engaged in FTD research<\/li>\n<li style=\"margin-top:6pt;margin-bottom:8pt\">The study aims to enroll and genetically test over 2,500 FTD patients across seven countries<\/li>\n<li style=\"margin-top:6pt;margin-bottom:8pt\">There are currently no FDA-approved treatments for FTD, one of the over 7,000 rare diseases affecting a total of over 350 million patients around the world<\/li>\n<\/ul>\n<p>CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb.  21, 2023  (GLOBE NEWSWIRE) &#8212; Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has extended and expanded the observational <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gmAYbkr4ARfrc7gtYil5aYYQMmph1yvQSR9AXxMPlg29IR-MmpxRa3cwYhae6ckNS-qkb1zfw2jvamd4QKAYKZI34XOOGuBjggqNte-gzg8jn7Xl4LG-Z_bbkww1WopCEjYPcrIBagk0WkHr1TMF-Do4PEfc2WEbXKnaEDd2PjVNY6CwAdGzbN8U8OhZM96SuM53vbDKqKikplxg1W2KjQ==\" rel=\"nofollow noopener\" target=\"_blank\">EFRONT Study<\/a> to advance the genetic understanding of frontotemporal dementia (FTD).<\/p>\n<p>The announcement comes in the lead-up to Rare Disease Day (RDD) on February 28. Since 2008, RDD has been held annually on the last day of February and includes a range of activities and initiatives throughout the month. Bringing together physicians, patient organizations, researchers, medical companies, and of course, rare disease patients from around the world, RDD raises awareness and serves as an opportunity to generate change for the rare disease community.<\/p>\n<p>Leveraging CENTOGENE\u2019s extensive network of approximately 30,000 active physicians, the EFRONT study aims to enroll and complete data-rich genetic testing for over 2,500 FTD diagnosed or suspected patients to learn more about the genetic makeup of the disease. As part of this ongoing work, the EFRONT study will expand its efforts across seven countries \u2013 increasing access to clinicians actively engaged in FTD research. The EFRONT study is being conducted with support from Alector, Inc., a clinical-stage biotechnology company pioneering immuno-neurology.<\/p>\n<p>EFRONT study participants with genetic mutations in the progranulin (<em>GRN<\/em>) gene will have the option to enroll in Alector\u2019s Phase 3 INFRONT-3 clinical trial of latozinemab, an investigational therapeutic candidate designed to increase progranulin levels for the treatment of FTD.<\/p>\n<p>\u201cFrontotemporal dementia is a rapidly progressing neurodegenerative disease, with no FDA-approved treatments,\u201d said Kim Stratton, Chief Executive Officer at CENTOGENE. \u201cAt CENTOGENE, we are committed to establishing a more inclusive and comprehensive approach from the very beginning of the pipeline to the end. This can only be achieved using diverse knowledge of rare and neurodegenerative diseases, which can be sourced from the CENTOGENE Biodatabank, from diagnostics to drug discovery, development, and commercialization.\u201d<\/p>\n<p>Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Alector is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain\u2019s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies.<\/p>\n<p>\u201cFrontotemporal dementia is a devastating disease for which new treatment options are urgently needed,\u201d said Gary Romano, M.D., Ph.D., Chief Medical Officer of Alector. \u201cThe EFRONT study helps us understand the genetic factors of the disease with the ultimate goal of advancing therapeutic options for patients living with FTD.\u201d<\/p>\n<p>\n        <strong>About Frontotemporal Dementia (FTD)<\/strong>\n      <\/p>\n<p>FTD is a rare neurodegenerative disease and the most common form of dementia for people under the age of 60. It affects an estimated 50,000 to 60,000 people in the United States and roughly 110,000 in the European Union. There are multiple heritable forms of FTD, including FTD-<em>GRN<\/em>. Patients with FTD frequently develop symptoms such as behavioral changes, lapses in judgment, and diminished language skills when they are in their 40\u2019s and 50\u2019s, with the disease running its course in 7-10 years. There are no FDA-approved treatment options available for any form of FTD.<\/p>\n<p>\n        <strong>About the EFRONT Study<\/strong>\n      <\/p>\n<p>The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gmAYbkr4ARfrc7gtYil5aS5HxBxkeaMrUe6DYngptJ7PMvGVR2L-Qn47uRkcgWYFFa6Wc1YD1UuHR2Lc7iXqYd5g4xAWJg9YFICvw-sf-tLkJpQ2usxZqrxu2TS1ssk7NS9ggZS9XPcYTKK2tJFfgq2XQWVdg_6LqC3EwtJpRuCwvHcpIehaYNsMvSq3dRRb2gsr0iXuQY4VA1RfmX9Hwg==\" rel=\"nofollow noopener\" target=\"_blank\">EFRONT Study<\/a> is a single visit, multi-center, non-interventional study that investigates the prevalence of genetic etiologies in frontotemporal dementia (FTD) by genotyping patients diagnosed with or suspected of FTD.<\/p>\n<p>FTD is a genetically and pathologically heterogeneous neurodegenerative disease caused by the loss or damage of nerve cells in the brain\u2019s frontal and temporal lobes. As a result, there are abnormalities in behavior, personality, and language comprehension problems, like lack of interest, judgment, loss of empathy, and apathy.<\/p>\n<p>To learn more about how you can enroll in the EFRONT Study, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NGmRX208_jp_ynqYB4E1sCYOyxv3VlHYbAvTsHRizYgWmbKH879TxFR44keon455sTuLX26jfV2KGa2nBERp9C3jkte-B-uOwjR9EcXRNTu9IwoGFAZHIwpkCmTDnQjTNo8VXXVT7sJQLHvdnMWOve2KmALXTBv_xTgDDtRIURA=\" rel=\"nofollow noopener\" target=\"_blank\">ClinicalTrials.gov<\/a>.<\/p>\n<p>\n        <strong>About Rare Disease Day (RDD)<\/strong>\n      <\/p>\n<p>RDD\u00a0has been held annually on the last day of February since 2008 \u2013 approaching its 16-year anniversary and underlining the incredible efforts of the rare disease community. Traditionally, RDD shines a spotlight on the extraordinary challenges posed by these often serious and hereditary conditions \u2013 raising awareness amongst healthcare providers, policymakers, and the general public.<\/p>\n<p>To learn more about rare diseases and how you can get involved with RDD 2023, visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WDKPhBcUHzZEQekWl8L3pt9v2TCd67RsJoN__pWswv9p4zIqpOMs4HbNfZAnmWK2th4FiNiIq_JDeAhw_36gc1BjMCoM-Z_CbzTqllKTSj4=\" rel=\"nofollow noopener\" target=\"_blank\">rarediseaseday.org<\/a><\/p>\n<p>\n        <strong>About CENTOGENE <\/strong>\n      <\/p>\n<p>CENTOGENE\u2019s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank \u2013 providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.<\/p>\n<p>Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis \u2013 building a network of approximately 30,000 active physicians. Our ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This data is captured in our CENTOGENE Biodatabank, with nearly 700,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 260 peer-reviewed publications.<\/p>\n<p>By translating our data and expertise into tangible insights, we have supported over 50 collaborations with pharma partners. Together, we accelerate and de-risk drug discovery, development, and commercialization in target &amp; drug screening, clinical development, market access and expansion, as well as offering CENTOGENE Biodatabank Licenses and Insight Reports to enable a world healed of all rare and neurodegenerative diseases.<\/p>\n<p>To discover more about our products, pipeline, and patient-driven purpose, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OHKuWGS-MNJy4AFk6sCIkFIsV5cIKqTJADKA53DjwfWT9qC9TF3cqtEBO9Sp0Zl4sZtQPhTuGQrabKkPZHh2PA==\" rel=\"nofollow noopener\" target=\"_blank\">www.centogene.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zRGpnkiwZAgnLIqE8EjlcqYnhI2UQTtNJk8gscaJPxWqiN_WDUA_DZ_ElPZnqsj7yoyMda4ZILpxNCO5yNtElecnPRRBkj2w5F-dEWXzTgg=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p>This press release contains \u201cforward-looking statements\u201d within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinues,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cproject,\u201d and similar expressions and future or conditional verbs such as \u201cwill,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201ccan,\u201d and \u201cmay,\u201d are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause CENTOGENE\u2019s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth, execute our business strategy and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our continued ongoing compliance with covenants linked to financial instruments, our requirement for additional financing, or other factors. For further information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to CENTOGENE\u2019s business in general, see CENTOGENE\u2019s risk factors set forth in CENTOGENE\u2019s Form 20-F filed on March 31, 2022, with the Securities and Exchange Commission (the \u201cSEC\u201d) and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and CENTOGENE\u2019s specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.<\/p>\n<p>\n        <strong>Contact:<\/strong>\u00a0\u00a0<\/p>\n<p>\n        <strong>CENTOGENE<\/strong>\u00a0\u00a0<\/p>\n<p>Ben Legg\u00a0<br \/>Corporate Communications\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8RJYFEFwRjNOrGb7qm8JQzSE-JiAFQY4XetDwECOypgzI_acHP4XwBVScWTdm3a8_Z713wjdsnlEdLkC8lBs4pO0LYqxaOKoW8dA4H_LirI=\" rel=\"nofollow noopener\" target=\"_blank\">Press@centogene.com<\/a><\/p>\n<p>Lennart Streibel<br \/>Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SVZzBlsrR793IGkM6LrYo7-9_Th7IeXSNQHy6RqfnqCc__u9HyUzBrdyigYA5lMPEsVgNjYoV_G3Qck1r5awJw==\" rel=\"nofollow noopener\" target=\"_blank\">IR@centogene.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzQyMCM1NDE4OTU0IzIxMjU1NDg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDA3ZTliNGEtNDc2Ny00YWNkLTljMjYtNDA1ZTEzNjBiYjk0LTExMzcxMTk=\/tiny\/Centogene-NV.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FTD is a rare and rapidly progressing neurodegenerative disease caused by multiple hereditary factors, including mutations in the progranulin (GRN) gene The observational EFRONT study is increasing the number of sites to expand access to geographic specific clinicians actively engaged in FTD research The study aims to enroll and genetically test over 2,500 FTD patients across seven countries There are currently no FDA-approved treatments for FTD, one of the over 7,000 rare diseases affecting a total of over 350 million patients around the world CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has extended &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-732825","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FTD is a rare and rapidly progressing neurodegenerative disease caused by multiple hereditary factors, including mutations in the progranulin (GRN) gene The observational EFRONT study is increasing the number of sites to expand access to geographic specific clinicians actively engaged in FTD research The study aims to enroll and genetically test over 2,500 FTD patients across seven countries There are currently no FDA-approved treatments for FTD, one of the over 7,000 rare diseases affecting a total of over 350 million patients around the world CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has extended &hellip; Continue reading &quot;In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-21T11:33:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzQyMCM1NDE4OTU0IzIxMjU1NDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)\",\"datePublished\":\"2023-02-21T11:33:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\\\/\"},\"wordCount\":1375,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MzQyMCM1NDE4OTU0IzIxMjU1NDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\\\/\",\"name\":\"In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MzQyMCM1NDE4OTU0IzIxMjU1NDg=\",\"datePublished\":\"2023-02-21T11:33:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MzQyMCM1NDE4OTU0IzIxMjU1NDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MzQyMCM1NDE4OTU0IzIxMjU1NDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/","og_locale":"en_US","og_type":"article","og_title":"In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD) - Market Newsdesk","og_description":"FTD is a rare and rapidly progressing neurodegenerative disease caused by multiple hereditary factors, including mutations in the progranulin (GRN) gene The observational EFRONT study is increasing the number of sites to expand access to geographic specific clinicians actively engaged in FTD research The study aims to enroll and genetically test over 2,500 FTD patients across seven countries There are currently no FDA-approved treatments for FTD, one of the over 7,000 rare diseases affecting a total of over 350 million patients around the world CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has extended &hellip; Continue reading \"In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-21T11:33:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzQyMCM1NDE4OTU0IzIxMjU1NDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)","datePublished":"2023-02-21T11:33:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/"},"wordCount":1375,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzQyMCM1NDE4OTU0IzIxMjU1NDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/","name":"In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzQyMCM1NDE4OTU0IzIxMjU1NDg=","datePublished":"2023-02-21T11:33:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzQyMCM1NDE4OTU0IzIxMjU1NDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzQyMCM1NDE4OTU0IzIxMjU1NDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in-the-lead-up-to-rare-disease-day-centogene-expands-observational-study-to-advance-the-genetic-understanding-of-frontotemporal-dementia-ftd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=732825"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732825\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=732825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=732825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=732825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}